Amarin Corp. (AMRN) Misses Q4 EPS by 4c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amarin Corp. (AMRN) Begins Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
March 1, 2018 5:52 AM ESTAmarin Corporation plc (NASDAQ: AMRN) today announced that final study-related visits have commenced for patients enrolled in its REDUCE-IT cardiovascular outcomes study. An important step in completion of this potentially landmark study is to have patients return to their clinical sites for final study data... More
